Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: Maintenance therapy for Crohn disease features the use of immunosuppressive drugs, which are associated with an increased risk of infection. Identification of safe and effective maintenance strategies is a priority.
Objective: To determine whether the oral administration of omega-3 free fatty acids is more effective than placebo for prevention of relapse of Crohn disease.
Design, Setting, And Patients: Two randomized, double-blind, placebo-controlled studies (Epanova Program in Crohn's Study 1 [EPIC-1] and EPIC-2) conducted between January 2003 and February 2007 at 98 centers in Canada, Europe, Israel, and the United States. Data from 363 and 375 patients with quiescent Crohn disease were evaluated in EPIC-1 and EPIC-2, respectively.
Interventions: Patients with a Crohn's Disease Activity Index (CDAI) score of less than 150 were randomly assigned to receive either 4 g/d of omega-3 free fatty acids or placebo for up to 58 weeks. No other treatments for Crohn disease were permitted.
Main Outcome Measure: Clinical relapse, as defined by a CDAI score of 150 points or greater and an increase of more than 70 points from the baseline value, or initiation of treatment for active Crohn disease.
Results: For EPIC-1, 188 patients were assigned to receive omega-3 free fatty acids and 186 patients to receive placebo. Corresponding numbers for EPIC-2 were 189 and 190 patients, respectively. The rate of relapse at 1 year in EPIC-1 was 31.6% in patients who received omega-3 free fatty acids and 35.7% in those who received placebo (hazard ratio, 0.82; 95% confidence interval, 0.51-1.19; P = .30). Corresponding values for EPIC-2 were 47.8% and 48.8% (hazard ratio, 0.90; 95% confidence interval, 0.67-1.21; P = .48). Serious adverse events were uncommon and mostly related to Crohn disease.
Conclusion: In these trials, treatment with omega-3 free fatty acids was not effective for the prevention of relapse in Crohn disease.
Trial Registration: clinicaltrials.gov Identifiers: EPIC-1: NCT00613197, EPIC-2: NCT00074542.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.299.14.1690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fortifying an emulsified meat product with co-encapsulated omega-3 fatty acids and lutein.
Food Res Int
November 2025
Department of Animal Science, Iowa State University, Ames, IA 50011, United States. Electronic address:
Lutein and omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), offer significant health benefits, especially when consumed together. However, their incorporation in food is often low due to their instability during processing and storage. Meat products play an essential role in human nutrition and are generally deficient in lutein and omega-3 fatty acids.
View Article and Find Full Text PDFMediterranean diet and associated metabolite signatures in relation to MASLD progression: A prospective cohort study.
Hepatol Commun
September 2025
Department of Epidemiology and Biostatistics, Clinical Big Data Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
Background: Mediterranean diet (MED) is recommended for managing metabolic dysfunction-associated steatotic liver disease (MASLD). However, associations between MED adherence, related metabolite signatures, and risks of liver-related events (LRE) and mortality in MASLD patients remain unclear.
Methods: We performed a prospective analysis using UK Biobank data, including 47,429 MASLD participants free of LRE at baseline.
Benefits, Challenges, and an Alternative Model of Fish Oil Enrichment in Animal-Based Food Products:A Review.
J Oleo Sci
August 2025
Faculty of Bioresource Sciences, Prefectural University of Hiroshima.
Fish oil (FO) has garnered attention in recent decades because of its omega-3 fatty acid (n-3 FAs) content, which is essential for healthy functions. However, the broad application of FO in food products has pros and cons because n-3 FAs are highly prone to oxidative deterioration, leading to product rejection. Enriching food products with FO is an effective strategy to boost the accumulation of n-3 FAs in the body.
View Article and Find Full Text PDFEicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particles.
Cardiovasc Res
August 2025
Elucida Research, Beverly, MA, USA.
Aims: Elevated Lp(a) levels increase cardiovascular (CV) risk. Lp(a) contains oxidized phospholipids that may promote lipid oxidation more than other lipoproteins. The highly unsaturated omega-3 fatty acid EPA has multiple double bonds that can trap free radicals in resonance structures.
View Article and Find Full Text PDFDocosahexaenoic Acid Inhibits Osteoclastogenesis via FFAR4-Mediated Regulation of Inflammatory Cytokines.
Molecules
July 2025
Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
Osteoclastogenesis-the activation and differentiation of osteoclasts-is one of the pivotal processes of bone remodeling and is regulated by RANKL/RANK signaling, the decoy function of osteoprotegerin (OPG), and a cascade of pro- and anti-inflammatory cytokines. The disruption of this balance leads to pathological bone loss in diseases such as osteoporosis and rheumatoid arthritis. FFAR4 (Free Fatty Acid Receptor 4), a G protein-coupled receptor for long-chain omega-3 fatty acids, has been confirmed as a key mediator of metabolic and anti-inflammatory effects.
View Article and Find Full Text PDF